From: Chapter 2, Molecular Genetics of Secondary Glioblastoma
Copyright: The Authors.
Licence: This open access article is licenced under Creative Commons Attribution 4.0 International (CC BY 4.0). https://creativecommons.org/licenses/by-nc/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 Sep 27. doi: 10.15586/codon.glioblastoma.2017.ch2
TABLE 1Key Characteristics of IDH-Wildtype and IDH-Mutant Glioblastomas (adapted from Ref. (5).)
| IDH-WT GBM | IDH-mutant GBM | |
|---|---|---|
| Synonym | Primary glioblastoma | Secondary glioblastoma |
| Precursor lesion | Identified de novo | Diffuse astrocytoma Anaplastic astrocytoma |
| Proportion of glioblastomas | ~90% | ~10% |
| Median age at diagnosis | ~62 years | ~44 years |
| M:F ratio | 1.42:1 | 1.05:1 |
| Median length of clinical history at diagnosis | 4 months | 15 months |
| Median overall survival | ||
| Surgery + radiotherapy | 9.9 months | 24 months |
| Surgery + RT + CTX | 15 months | 31 months |
| Location | Supratentorial | Preferentially frontal |
| Necrosis | Extensive | Limited |
| TERT promoter mutations | 72% | 26% |
| TP53 mutations | 27% | 81% |
| ATRX mutations | Exceptional | 71% |
| EGFR amplification | 35% | Exceptional |
| PTEN mutations | 24% | Exceptional |
ATRX, adult thalassemia mental retardation x-linked; CTX, chemotherapy; EGFR, epidermal growth factor receptor; GBM, Glioblastoma multiforme; IDH, Isocitrate dehydrogenase; PTEN, phosphatase and tensin homolog; TERT, telomerase reverse transcriptase; TP53, tumor protein 53; RT, radiotherapy.
- PubMedLinks to PubMed
- Review Glioblastoma: pathology, molecular mechanisms and markers.[Acta Neuropathol. 2015]Review Glioblastoma: pathology, molecular mechanisms and markers.Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Acta Neuropathol. 2015 Jun; 129(6):829-48. Epub 2015 May 6.
- Review Molecular genetics of gliomas.[Cancer J. 2014]Review Molecular genetics of gliomas.Appin CL, Brat DJ. Cancer J. 2014 Jan-Feb; 20(1):66-72.
- Review Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis.[Adv Anat Pathol. 2015]Review Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis.Appin CL, Brat DJ. Adv Anat Pathol. 2015 Jan; 22(1):50-8.
- Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma.[Neuro Oncol. 2007]Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma.Wiencke JK, Zheng S, Jelluma N, Tihan T, Vandenberg S, Tamgüney T, Baumber R, Parsons R, Lamborn KR, Berger MS, et al. Neuro Oncol. 2007 Jul; 9(3):271-9. Epub 2007 May 15.
- Review Biomarker-driven diagnosis of diffuse gliomas.[Mol Aspects Med. 2015]Review Biomarker-driven diagnosis of diffuse gliomas.Appin CL, Brat DJ. Mol Aspects Med. 2015 Nov; 45:87-96. Epub 2015 May 21.
- TABLE 1, Key Characteristics of IDH-Wildtype and IDH-Mutant Glioblastomas (adapt...TABLE 1, Key Characteristics of IDH-Wildtype and IDH-Mutant Glioblastomas (adapted from Ref. (5).) - Glioblastoma
Your browsing activity is empty.
Activity recording is turned off.
See more...